The Center for Breakthrough Medicines (CBM) has announced a multi-year deal with Achilles Therapeutics in the UK, reports John George for the Philadelphia Business Journal.
The partnership will provide expanded cell therapy manufacturing capabilities required to supply products for biopharmaceutical company Achilles’ ongoing Phase I/IIa clinical trials in advanced non-small cell lung cancer and metastatic or recurrent melanoma patients.
“We are bringing together two powerful, experienced cell therapy organizations for the benefit of cancer patients,” said John Lee, Ph.D., Vice President, Head of Cell Therapy of the King of Prussia company. “We look forward to mobilizing our world-class cell therapy capabilities, with our first wave of cell therapy suites to enable Achilles to accelerate the development of their flagship precision T cell product candidate.”
CBM will manufacture the UK company’s precision T cell therapy for the company’s ongoing clinical trials in non-small cell lung cancer and melanoma patients.
“Achilles is thrilled to partner with CBM given their experience, capabilities, available cell therapy capacity and strategic location. After opening our US headquarters in Philadelphia, CBM’s King of Prussia location was perfect for our needs,” said Edward Samuel, the Executive Vice President of Technical Operations at Achilles Therapeutics.
Read more about the partnership with King of Prussia’s Center for Breakthrough Medicines and UK’s Achilles Therapeutics at the Philadelphia Business Journal.